RT Journal Article
SR Electronic
T1 Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e003154
DO 10.1136/jitc-2021-003154
VO 9
IS 8
A1 Paolo Bossi
A1 Cristina Gurizzan
A1 Luigi Lorini
A1 Pierluigi di Mauro
A1 Chiara Sardini
A1 Marco Merlano
YR 2021
UL http://jitc.bmj.com/content/9/8/e003154.abstract
AB Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies to elucidate their potential positive or negative consequences on the outcomes when administered with immunotherapeutic agents.